IGF Binding Protein-2 (IGFBP-2)

Test Code

IGFBP2

Quest Code

37102

CPT Codes
83519

Preferred Specimen

1 mL serum

Patient Preparation
Fasting is preferred

Minimum Volume

0.2 mL

Transport Temperature

Refrigerated (cold packs)

Specimen Stability

Room temperature: 12 hours
Refrigerated: 4 days
Frozen: 28 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Gross hemolysis • Gross lipemia • Received room temperature

Methodology
Radioimmunoassay (RIA)

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: Tues; Report available: 4-11 days

Reference Range

Adult

18-49 Years	38-267 ng/mL
>49 Years	47-350 ng/mL

Pediatric

5-9 Years	49-208 ng/mL
10-13 Years	41-167 ng/mL
14-17 Years	37-135 ng/mL

Clinical Significance

This test measures serum concentration of insulin-like growth factor binding protein 2 (IGFBP-2). The value of testing IGFBP-2 has been researched for various disorders, including obesity, type 2 diabetes, cancer, and Alzheimer disease [1,2].

IGFBP-2 belongs to the IGFBP family of 6 proteins that bind and transport insulin-like growth factors (IGFs) and regulate IGF bioavailability. IGFBP-2 is present in very high concentrations during fetal development, progressively falling after birth. Among the 6 IGFBPs, IGFBP-2 has been involved in the IGF activity in most organs, and its role, either dependent or independent of IGFs, has been implicated in bone growth, metabolism, and malignancy [1].

The clinical application of IGFPB-2 measurement was explored in numerous studies but has not been well-established. IGFBP-2 is the most abundantly expressed IGFBPs in several cancers, such as glioma, prostate, breast, and ovarian cancers, possibly contributing to the aggressiveness of these cancers [1]. Low levels of IGFBP-2 are associated with obesity, type 2 diabetes mellitus, and metabolic syndrome [1]. The therapeutic potential of IGFPB-2 has been investigated preclinically in increasing insulin sensitivity, decreasing adipogenesis, and inhibiting tumor growth and metastasis.

Additionally, IGFBP-2 levels were correlated with cognitive outcomes, possibly by inhibiting the neuroprotective effects of IGFs in the brain. Cognitively healthy adults with elevated levels of IGFBP-2 may have higher risk to develop all-cause dementia and Alzheimer disease dementia [2]. Therefore, IGFBP-2 has been suggested as a potential risk predictor and therapeutic candidate for dementia [2].

The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.

References
1. Yau SW, et al. J Cell Commun Signal. 2015;9(2):125-142.
2. McGrath ER, et al. Ann Clin Transl Neurol. 2019;6(9):1659-1670.

Performing Laboratory

Quest Diagnostics Nichols Institute-San Juan Capistrano, CA

33608 Ortega Highway

San Juan Capistrano, CA 92675-2042

Last Updated: June 16, 2023

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.